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Abstract
Background: Adrenomedullin (ADM) exerts its biological functions through the receptor-mediated enzymatic
mechanisms that involve protein kinase A (PKA), or neuronal nitric oxide synthase (nNOS). We previously
demonstrated that the receptor-mediated cAMP/PKA pathway involves in ADM-enhanced baroreceptor reflex (BRR)
response. It remains unclear whether ADM may enhance BRR response via activation of nNOS-dependent
mechanism in the nucleus tractus solitarii (NTS).
Methods: Intravenous injection of phenylephrine was administered to evoke the BRR before and at 10, 30, and 60
min after microinjection of the test agents into NTS of Sprague-Dawley rats. Western blotting analysis was used to
measure the level and phosphorylation of proteins that involved in BRR-enhancing effects of ADM (0.2 pmol) in
NTS. The colocalization of PKA and nNOS was examined by immunohistochemical staining and observed with a
laser confocal microscope.
Results: We found that ADM-induced enhancement of BRR response was blunted by microinjection of NPLA or
Rp-8-Br-cGMP, a selective inhibitor of nNOS or protein kinase G (PKG) respectively, into NTS. Western blot analysis
further revealed that ADM induced an increase in the protein level of PKG-I which could be attenuated by
co-microinjection with the ADM receptor antagonist ADM22-52 or NPLA. Moreover, we observed an increase in
phosphorylation at Ser1416 of nNOS at 10, 30, and 60 min after intra-NTS administration of ADM. As such,
nNOS/PKG signaling may also account for the enhancing effect of ADM on BRR response. Interestingly, biochemical
evidence further showed that ADM-induced increase of nNOS phosphorylation was prevented by co-microinjection
with Rp-8-Br-cAMP, a PKA inhibitor. The possibility of PKA-dependent nNOS activation was substantiated by
immunohistochemical demonstration of co-localization of PKA and nNOS in putative NTS neurons.
Conclusions: The novel finding of this study is that the signal transduction cascade that underlies the
enhancement of BRR response by ADM in NTS is composed sequentially of cAMP/PKA and nNOS/PKG pathways.
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Adrenomedullin (ADM), a 52-amino acid peptide, was
originally isolated from human pheochromocytoma and
initially shown to have potent vasodilatory activity [1].
The physiologic and pharmacologic functions of ADM
have been intensively investigated after its discovery (for
review see [2]). ADM exerts multiple biological activities
by acting on its specific receptors, composed of calcito-
nin receptor-like receptor (CRLR) and receptor activity
modifying protein (RAMP)-2 or -3 [3]. The hypotensive
effect of intravenously administered ADM has been
attributed to activation of ADM receptors (ADMRs)
located on blood vessels [1]. In addition to distribution
in the cardiovascular system, ADM and ADMRs are also
expressed in the central nervous system (CNS) and are
particularly localized to the autonomic nuclei, including
nucleus tractus solitarii (NTS), lateral parabrachial
nucleus (LPBN), and rostral ventrolateral medulla
( R V L M )[ 4 - 6 ] .T h e s ef i n d i n g ss u g g e s t e dap o s s i b l er o l e
for ADM in central regulation of cardiovascular func-
tions. Indeed, several studies demonstrated that microin-
jection of ADM into the CNS induces brain area-specific
changes in arterial pressure and heart rate (HR) [7,8].
Other studies further indicated that central ADM also
exhibits an area-specific regulation on the baroreceptor
reflex (BRR) in anesthetized or conscious animals [9-11].
In our recent study [12], we demonstrated that microin-
jection of ADM into NTS, the termination site of primary
baroreceptor afferents in the brain stem [13], significantly
increases BRR response and sensitivity in a time- and
dose-dependent manner, without producing discernible
changes in basal arterial pressure and heart rate.
Stimulation of cyclic adenosine monophosphate
(cAMP) formation is suggested to be the primary down-
stream mechanism subsequent to activation of the Gs
protein-coupled ADMRs in vascular cells [1,14]. In CNS
neurons, the cAMP-associated mechanism is also consid-
ered to be the primary signaling pathway that mediates
ADM actions. Xu and Krukoff reported that ADM inhi-
bits the baroreflex control of HR via activation of cAMP-
dependent protein kinase A (PKA) in RVLM of the rat
[11]. Our previous study also revealed the involvement of
cAMP/PKA-dependent mechanism in BRR augmentation
in response to activation of ADMRs in NTS [12]. In addi-
tion to cAMP/PKA pathway, nitric oxide (NO) has been
suggested to serve as another intracellular signaling
molecule that mediates the ADM actions [2]. In RVLM
and LPBN, ADM induces hypertensive effect through
cyclic guanosine monophosphate (cGMP)-associated sig-
naling that is mediated by NO derived from neuronal
NO synthase (nNOS) [15,16]. However, whether the
nNOS-dependent mechanism contributes to the BRR-
enhancing effect of ADM in NTS remains unclear.
The present study was undertaken to evaluate the
hypothesis that ADM may enhance BRR through PKA-
dependent activation of nNOS in NTS. Our results sup-
port this hypothesis and reveal that nNOS may mediate
ADM-induced BRR enhancement via activation of
cGMP-dependent protein kinase G (PKG) in NTS. We
further found that a PKA-dependent phosphorylation at
the amino acid residue Ser1416 accounts for the ADM-
induced nNOS activation.
Materials and methods
Animals
Sprague-Dawley rats (male, weighing 300-400 g)
obtained from the Animal Center of National Yang-
Ming University were used in this study. Rats were
housed in a laboratory animal room under controlled
temperature (25°C) and light on 0800-2000 h, and had
unrestricted access to food and water. All animals were
allowed to acclimatize for at least 3 days before use.
Animal care and all experimental protocols applied in
the present study were approved by the Institutional
Animal Care and Use Committee of National Yang-
Ming University.
Surgical preparation
As described previously [12], rats were anesthetized by
intraperitoneal (i.p.) injection of pentobarbital sodium
(50 mg/kg) and placed on a heating pad. The trachea
was intubated to facilitate ventilation, and the femoral
artery was cannulated for monitoring systemic arterial
pressure (SAP). The femoral veins on both sides were
also cannulated for injection of test agents and adminis-
tration of supplemental anesthetics. Mean AP (MAP,
mmHg) and HR (beats/min) were derived from the pul-
satile SAP signals measured with a pressure transducer
(T844, ADInstruments, Castle Hill, Australia). To pro-
vide satisfactory anesthetic maintainance [17], rats
received continuous infusion of pentobarbital at a rate
of 15-20 mg/kg/h throughout the recording session.
Microinjection
The rat was placed in a stereotaxic frame (Kopf,
Tujunga, CA, USA) followed by an occipital craniotomy
to expose the dorsal surface of the medulla. A glass pip-
ette adapted to a Hamilton microsyringe (Reno, NV,
USA) was used to microinject test agents into NTS. The
coordinates used were: 0.5 mm rostral to the calamus
scriptorius, ±0.5 mm lateral to the midline, and 0.5 mm
below the surface of the medulla. The volume of injec-
tion was limited to 20 nl per site. For histological verifi-
cation of injection sites, the microinjection medium for
test agents or artificial cerebrospinal fluid (aCSF) con-
tains 1% Evans blue.
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ADM was purchased from Bachem AG (Hauptstrasse,
Bubendorf, Switzerland); N-propyl-L-arginine (NPLA),
S-methylisothiourea (SMT), L-NIO or 8-bromo-cAMP
(8-Br-cAMP) from Tocris (Bristol, UK); Rp-8-bromo-
cAMP (Rp-8-Br-cAMP) or Rp-8-bromo-cGMP (Rp-8-
Br-cGMP) from Calbiochem (San Diego, CA, USA);
ADM22-52, 3-morpholinosyndnomine (SIN-1), S-nitroso-
glutathione (GSNO) or phenylephrine from Sigma-
Aldrich (St. Louis, MO, USA); and L-NAME from
Cayman (Ann Arbor, MI, USA).
Measurement of BRR response
The procedures and methods for measuring the BRR
response were described previously [12]. In brief, a
bolus intravenous injection of phenylephrine (10 μg/kg)
was administered to evoke the BRR before and 10, 30 or
60 min after microinjection of the test agent into NTS.
The BRR response was represented by the ratio of the
peak magnitude of reflex bradycardia to the peak magni-
tude of phenylephrine-induced pressor response. The
averaged value of BRR response obtained from three
injections of phenylephrine prior to microinjection of
the test agent served as the baseline control.
Histology
At the end of the physiological experiments, animals
were killed with a high dose of pentobarbital sodium
(100 mg/kg, i.p.). The brain stem was then removed and
fixed in 10% paraformaldehyde-saline solution that con-
tains 30% sucrose for 48-72 h. Serial sections were cut
(20 μm) in a cryostat (Leica, Wetzlar, Germany) and
mounted on slides. The sections were then stained with
neutral red, and the microinjection site (marked with
Evans blue) was identified under a microscope.
Immunofluorescence staining
The procedures of triple immunofluorescence staining
were described in a previous study [12]. Briefly, rats
were deeply anesthetized and perfused transcardially
with warm heparinized saline, followed by ice cold 4%
paraformaldehyde (pH 7.4). Brains were then rapidly
removed and postfixed at 4°C overnight. The medulla
oblongata at the level of obex was sectioned coronally at
a thickness of 10 μm. Sections were then incubated with
a mouse anti-nNOS antiserum (1:25; Santa Cruz Bio-
technology, Santa Cruz, CA USA) and a rabbit anti-PKA
antiserum (1:50; Santa Cruz Biotechnology) for 24 h at
4°C followed by 1-h incubation of Alexa Fluor 546-con-
jugated goat anti-mouse IgG (1:125; Invitrogen, CA,
USA) and Alexa Fluor 488-conjugated donkey anti-rab-
bit IgG (1:250; Invitrogen). Nuclear staining was per-
formed with 4’-6-diamidino-2-phenylindole (DAPI)
(1:250; Invitrogen, Carlsbad, CA, USA) in PBS for
10 min at room temperature. Immunoreactive expres-
sion of proteins was observed with a laser confocal
microscope (Leica, Wetzlar, Germany).
Western blotting
The experimental protocols for Western blot analysis of
ADM-induced protein expression were described pre-
viously [12]. In brief, tissues from separate groups of
rats obtained 10, 30 or 60 min after bilateral microinjec-
tions of aCSF or test agents into NTS were collected.
The tissues covering the anatomical boundaries of the
dorsomedial NTS were visualized and micropunched
with the aid of a dissecting microscope. After tissue
homogenization and protein quantification, proteins of
interest were separated using a 12% SDS-polyacrylamide
gel and transferred to a polyvinylidene difluoride (PVDF)
membrane. Following blocking of non-specific binding,
membranes were incubated with a rabbit anti-PKG-1a
antiserum (1:2000; Calbiochem/EMD Biosciences, Darm-
stadt, Germany), a rabbit anti-nNOS antiserum (1:1000;
Santa Cruz Biotechnology), a rabbit anti-phospho-nNOS
(Ser847) antiserum (1:3000; Abcam, Cambridge, UK), a
rabbit anti-phospho-nNOS (Ser1416) antiserum (1:3000;
Abcam), or a rabbit anti-b-actin antiserum (1:10000;
Santa Cruz Biotechnology) in Tris buffer at 4°C over-
night. This was followed by incubation with horseradish
peroxidase (HRP)-conjugated donkey anti-rabbit IgG
(1:10000; Santa Cruz Biotechnology) for 1 h at room
temperature. Western blots were quantified by densit-
ometer and the relative density of proteins of interest was
normalized against b-actin.
Statistical analysis
All data are presented as mean ± S.E.M. Results were
analyzed by one-way or two-way ANOVA with repeated
measures for group means, as appropriate, followed by
Scheffe’sp o s th o ct e s tf o ri n d i v i d u a lm e a n s .P <0 . 0 5
was taken as statistically significant.
Results
Involvement of nNOS in BRR-enhancing effect of ADM in
NTS
In our previous study [12], we have demonstrated that
microinjection of ADM (0.2 pmol) into NTS significantly
augmented BRR response with a maximal enhancement at
60 min after administration. Our first set of experiments
established the participation of nNOS in this process.
Microinjection bilaterally of ADM (0.2 pmol) into NTS eli-
cited a 1.4 fold increase in the BRR response (Figure 1A).
L-NAME (25 pmol) blunted completely the BRR-
augmenting effect of ADM (0.2 pmol) when co-microin-
jected with ADM (Figure 1A). However, L-NAME, when
given alone to NTS at 25 pmol, exerted minimal effect
on BRR response (Figure 1A). Comparable effects were
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pmol), a selective nNOS inihibitor (Figure 1B). On the
other hand, the ADM-induced BRR enhancement was
substantially unaffected by co-microinjections with the
relatively selective inducible NOS (iNOS) inhibitor SMT
(250 pmol) (Figure 1C), or L-NIO (100 pmol), a preferen-
tial endothelial NOS (eNOS) inhibitor (Figure 1D).
nNOS-dependent PKG activation by ADM and in NTS
Since PKG can be activated by nNOS-derived NO [18],
we next examined the role of PKG in the BRR enhance-
ment response induced by ADM in NTS. Figure 2A
shows that co-microinjection of Rp-8-Br-cGMP (1
nmol), a selective PKG inhibitor, abolished the ADM-
elicited BRR augmentation. Western blot analysis
revealed that ADM significantly increased PKG-I level
in NTS 30 min after application, and was diminished by
the ADMR antagonist ADM22-52 or NPLA (Figure 2B).
Phosphorylation of nNOS by ADM in NTS
Phosphorylation at critical amino acid residues is impor-
tant for the regulation of nNOS activity [19]. Since
ADM induces dephosphorylation of nNOS at Ser847
and stimulates NO production from cultured hypothala-
mic neurons [20], we examined the effect of ADM on
phosphorylation of nNOS at Ser847. As shown in Figure
3A, the protein level of total nNOS was not substantially
changed 10, 30, and 60 min after ADM administration.
We also found that the protein levels of phospho-nNOS
(Ser847) were not significantly altered during the time-
period when BRR response was augmented by ADM
(Figure 3A &3B).
Figure 1 Involvement of nNOS-dependent mechanism in the effect of ADM on BRR response. A: Temporal changes in BRR response of
the rat that received bilateral microinjections into NTS of aCSF, L-NAME (25 pmol), ADM (0.2 pmol) or ADM plus L-NAME. B: Temporal changes
in BRR response of the rat that received bilateral microinjections into NTS of aCSF, NPLA (250 pmol), ADM (0.2 pmol) or ADM plus NPLA. C:
Temporal changes in BRR response of the rat that received bilateral microinjections into NTS of aCSF, SMT (250 pmol), ADM (0.2 pmol) or ADM
plus SMT. D: Temporal changes in BRR response of the rat that received bilateral microinjections into NTS of aCSF, L-NIO (100 pmol), ADM (0.2
pmol) or ADM plus L-NIO. Data are presented as means ± SEM, n = 6 to 8 animals per group. * p < 0.05 compared with control; † p < 0.05
compared with the ADM group at 10, 30 or 60 mins.
Yen et al. Journal of Biomedical Science 2011, 18:32
http://www.jbiomedsci.com/content/18/1/32
Page 4 of 9In NTS, insulin-mediated cardiovascular effect was
reported to involve the nNOS activation via phosphory-
lation at Ser1416 [21]. As illustrated in Figure 3A, ADM
induced a significant increase in protein levels of phos-
pho-nNOS (Ser1416) in NTS. The ADM-induced
increase in phosphorylation of nNOS at Ser1416
m a x i m i z e da t3 0m i na n dg r a dually declined within 60
min after ADM administration (Figure 3B).
PKA-dependent activation of nNOS induced by ADM in
NTS
In addition to the nNOS/PKG pathway, we demon-
strated previously that the cAMP/PKA mechanism med-
iates the effects of ADM on baroreflex in NTS in rats
[12]. Since both PKA [12] and nNOS (Figure 1) inhibi-
tors abolished completely the ADM-elicited augmenta-
tion of BRR response, it is plausible that an in-series
relationship exists between PKA and nNOS signaling
pathways in the mediation of ADM effects in NTS. Our
fourth series of experiments was carried out to examine
whether nNOS phosphorylation is dependent on PKA
activation evoked by ADM in NTS. We found that
ADM-induced increase in phospho-nNOS (Ser1416)
level was completely suppressed by co-microinjection
with the PKA inhibitor Rp-8-Br-cAMP into NTS, while
the level of total nNOS remained unaltered (Figure 4).
Figure 2 Involvement of cGMP-dependent mechanism in the
effect of ADM on BRR response. A: Temporal changes in BRR
response of the rat that received bilateral microinjections into NTS
of aCSF, Rp-8-Br-cGMP (1 nmol), ADM (0.2 pmol) or ADM plus Rp-8-
Br-cAMP. Data are presented as means ± SEM; *p < 0.05 compared
with control; † p < 0.05 compared with the ADM group at 10, 30 or
60 mins. B: Representative gels (inset) and quantified data showing
changes in the protein level of active form PKG-I in NTS of the rat
at 30 min after receiving bilateral microinjections into NTS of aCSF,
ADM (0.2 pmol), ADM plus ADM22-52 (0.2 pmol), or ADM plus NPLA
(250 pmol). Quantified data are presented as means ± SEM. The
mean value of sham-operated control rats is represented as Basal. *
p < 0.05 compared with aCSF.
Figure 3 ADM-induced increase in phosphorylation of nNOS.A :
Representative Western blotting gels showing temporal changes in
phosphorylation at Ser847 (p-nNOS
S847) and Ser1416 of nNOS (p-
nNOS
S1416) at 10, 30, and 60 min after intra-NTS microinjection of
ADM (0.2 pmol). B: Quantified data showing temporal changes in
the protein level of phospho-nNOS in NTS of the rat that received
bilateral microinjections into NTS of aCSF (Control; sampled at 10
min after aCSF administration), or ADM (0.2 pmol). Data are
presented as means ± SEM. * p < 0.05 compared with control.
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nNOS activation to BRR augmentation. As illustrated in
Figure 5A, both 8-Br-cAMP (400 pmol), a PKA activator,
and SIN-1 (1 nmol), a putative NO donor, mimicked the
BRR-enhancing effect of 0.2 pmol ADM at 10-60 min
after microinjection into NTS. We further found that the
BRR enhancement induced by 8-Br-cAMP was comple-
tely blocked by L-NAME (Figure 5B). On the other hand,
the BRR-enhancing effect of SIN-1 was not altered by the
PKA inhibitor Rp-8-Br-cAMP (Figure 5B). Of note is that
the BRR augmentation by microinjection of GSNO
(0.5 nmol), a specific NO donor, was comparable to that
of SIN-1 and was also unaffected by co-microinjection
with Rp-8-Br-cAMP (Figure 5C).
To determine whether nNOS and PKA are co-loca-
lized at the same NTS neuron, double immunohisto-
chemical staining for nNOS and PKA proteins was
carried out in rat brain slices. As shown in Figure 6,
putative NTS neurons positively expressed nNOS-
immunoreactivity (IR) were also stained with immuno-
fluorescence for PKA protein, while some neurons man-
ifested PKA-IR alone.
Figure 4 ADM-induced PKA-dependent phosphorylation of
nNOS. Representative Western blotting gels showing changes in
phosphorylation at Ser1416 of nNOS (p-nNOS
S1416) at 10 min after
intra-NTS microinjection of aCSF (control), PKA inhibitor Rp-8-Br-
cAMP (PKAi; 1 nmol), ADM (0.2 pmol), or ADM plus PKAi. B:
Quantified data showing changes in the protein level of phospho-
nNOS in NTS of the rat that received bilateral microinjections into
NTS of aCSF, PKAi (1 nmol), ADM (0.2 pmol), or ADM plus PKAi. Data
are presented as means ± SEM. *p < 0.05 compared with control;
#p < 0.05 compared with the ADM group.
Figure 5 Involvement of PKA-dependent NOS activation in the
effect of ADM on BRR response. A: Temporal changes in BRR
response of the rat that received bilateral microinjections into NTS
of ADM (0.2 pmol), 8-Br-cAMP (400 pmol), or SIN-1 (1 nmol). B:
Temporal changes in BRR response of the rat that received bilateral
microinjections into NTS of aCSF, ADM (0.2 pmol), 8-Br-cAMP (400
pmol) plus L-NAME (25 pmol), or SIN-1 (1 nmol) plus Rp-8-Br-cAMP
(1 nmol). C: Temporal changes in BRR response of the rat that
received bilateral microinjections into NTS of aCSF, ADM (0.2 pmol),
GSNO (0.5 nmol), or GSNO plus Rp-8-Br-cAMP (1 nmol). Data are
presented as means ± SEM, n = 6 to 8 animals per group. * p <
0.05 compared with control at 10, 30 or 60 mins.
Yen et al. Journal of Biomedical Science 2011, 18:32
http://www.jbiomedsci.com/content/18/1/32
Page 6 of 9Discussion
The present study unveiled two novel findings. We
found that the activation of nNOS/PKG cascade is
responsible for BRR enhancement induced by microin-
jection of ADM into the NTS. We further showed that
activation of nNOS by ADM is via a PKA-dependent
mechanism. Together with our previous findings [12],
this study demonstrated that the signal transduction
cascade that underlies the enhancement of BRR
response by ADM in NTS is composed sequentially of
cAMP/PKA and nNOS/PKG pathways (Figure 7).
This is the first report that provides direct biochemical
and pharmacologic evidence to show that PKG-I, the
active form of PKG, in NTS was upregulated by ADM-
induced nNOS activation. NO participates in a wide
variety of neuronal functions in the CNS, including car-
diovascular regulation, nociception, synaptic plasticity,
and control of complex behavioral responses (for review
see [22]). At the NTS level, NO has been suggested to
affect neuronal discharge and modulate the BRR
response of the rat [23-26]. Although all three NOS iso-
forms have been suggested to be presented in the NTS
[27,28], the possibility that the activation of iNOS and
eNOS may be involved in ADM-induced BRR-enhancing
effect is deemed unlikely (Figure 1C &1D). Moreover,
several lines of evidence support the notion that nNOS-
derived NO in NTS plays important physiologic roles in
regulating transmission of arterial baroreflex signals and
Figure 6 Co-localization of PKA and nNOS proteins in NTS. Confocal microscopic images of NTS showing immunofluorescence staining for
nNOS (A, Alexa Fluor 546), PKA (B, Alexa Fluor 488), or cell nuclei (C, DAPI). The merged image (D) showing single staining for PKA (arrowhead)
or double immunofluorescence staining (yellow color) for PKA and nNOS (arrows). Scale bar: 25 μm.
Figure 7 Schematic model of cellular mechanisms underlying
the enhancement of BRR response by ADM in NTS. AC:
adenylate cyclase; ADM: adrenomedullin; ADMR: adrenomedullin
receptor; GC: guanylate cyclase; Gs: stimulatory GTP-binding protein;
nNOS: neuronal nitric oxide synthase; PKA: protein kinase A; PKG:
protein kinase G.
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strated in this study that the BRR-enhancing effect of
ADM is mediated by nNOS-dependent PKG activation
in NTS. We noted that the ADM-induced increase in
nNOS phosphorylation declined gradually at 60 min
after ADM microinjection, while the BRR-enhancing
effect was sustained at the comparable time period. The
discrepancy of temporal changes in nNOS activity and
BRR response may reflect the sequential participation of
nNOS and its downstream molecules including PKG in
the ADM-activated signaling cascades. The significance
of nNOS-dependent PKG activation in BRR regulation
is further substantiated by a previous study [18] that
revealed a significant nNOS-dependent upregulation of
PKG-I protein in NTS following baroreceptor activation.
Another novel finding of the present study is that
ADM may induce a PKA-dependent nNOS activation in
NTS to enhance the BRR response. Both cAMP/PKA
and NO/PKG mechanisms contribute to cardiovascular
regulations by ADM in RVLM [11,16]. We further
demonstrated these two signaling pathways exist in in-
series in NTS. Our immunohistochemical results also
showed that the PKA- and nNOS-dependent mechan-
isms could be activated in the same NTS neuron. We
recognized that some PKA-labled NTS neurons did not
expressed nNOS signal (Figure 6D). Recently, the extra-
cellular signal-regulated kinase (ERK)-dependent signal-
ing pathway in the NTS has been demonstrated to
modulate cardiovascular functions [31]. It is thus possi-
ble that the PKA-dependent ERK signaling, which could
be found in adipocytes activated by ADM [32], may
serve as the downstream mechanism responsible for
ADM-induced PKA activation in those NTS neurons
expressing PKA-immunoreactivity only. The nNOS-IR is
localized in neurons other than in glial cells [27] and is
highly co-localized with soluble guanylate cyclase in
NTS [33]. These results further substantiate our obser-
vations that ADM-activated nNOS/NO-cGMP/PKG cas-
cades could be resided in the same NTS neuron.
The enzyme activity of nNOS has been demonstrated to
be intimately associated with the state of phosphorylation
at the amino acid residues Ser847 and Ser1416 [19]. For
instance, phosphorylation of nNOS at Ser847 by calmodu-
lin-dependent kinases results in a decrease of its enzyme
activity [34]. On the other hand, protein phosphatase 2A-
mediated dephosphorylation at Ser847 can lead to the
activation of nNOS [35]. Recently, Xu and Krukoff
demonstrated in an in vitro study that ADM significantly
stimulated NO production from primary rat hypothalamic
neurons by dephosphorylation of nNOS at Ser847 through
a mechanism of PKA-dependent activation of phospha-
tases [20]. However, our results demonstrated that ADM
induced an increase in phosphorylation of nNOS at
Ser1416 but not at Ser847 in NTS neurons. The time
course of nNOS phosphorylation is also compatible with
the BRR-enhancing response induced by ADM. Since
phosphorylation of nNOS at Ser1416, a known phosphory-
lation site for Akt (protein kinase B), is an alternative way
to increase its enzyme activity [21], it is possible that Akt
signaling may be involved in PKA-dependent nNOS phos-
phorylation and contributed to the ADM-induced BRR
enhancement in NTS. This possibility, however, is sub-
jected to further delineation.
Conclusions
We have previously demonstrated an important role for
ADM in BRR enhancement that is mediated by a PKA-
dependent mechanism in theN T S[ 1 2 ] .I nt h ep r e s e n t
study, the effect of ADM on baroreflex was further sug-
gested to involve the activation of nNOS in NTS. We
conclude that the signal transduction cascade that
underlies the enhancement of BRR response by ADM in
NTS is composed sequentially of cAMP/PKA and
nNOS/PKG pathways. These findings may provide a
new insight for our understanding of ADM-elicited sig-
naling mechanisms and their cross-talk in central regu-
lation of cardiovascular functions.
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